Get started
Author

Rosa Vitale

Observed names: R. L. Vitale, Rosa Letizia Vitale
Institution: Nouscom (Italy)
ORCID: 0009-0003-3160-4560
Observed ORCID: 0009-0003-3160-4560
OpenAlex ID: A5087791595
Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus
1999 · Stéphane Bressanelli, Licia Tomei, et al. · Proceedings of the National Academy of Sciences · 616
A central hydrophobic domain of the hepatitis C virus NS4A protein is necessary and sufficient for the activation of the NS3 protease
1996 · L. Tomei, C. Failla, et al. · Journal of General Virology · 101
Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade
2019 · Anna Morena D’Alise, Guido Leoni, et al. · Nature Communications · 99
PDF
A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability
2020 · Guido Leoni, Anna Morena D'Alise, et al. · Cancer Research · 91
Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses
2024 · Anna Morena D'Alise, Guido Leoni, et al. · Clinical Cancer Research · 53
PDF
Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
2021 · Anna Morena D'Alise, Guido Leoni, et al. · Journal for ImmunoTherapy of Cancer · 15
PDF
Abstract LB196: NOUS-PEV, a personalized cancer immunotherapy targeting neoantigens, induces long lasting, tumor infiltrating memory T cells
2023 · Oliver Bechter, Anna Morena D'Alise, et al. · Cancer Research · 5
706 NOUS-PEV, a novel personalized viral-based prime/boost cancer immunotherapy targeting patient-specific neoantigens: interim results from the first subjects in the phase 1b study
2022 · Oliver Bechter, Juan Martin-Liberal, et al. · Journal for ImmunoTherapy of Cancer · 4
PDF
Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine
2024 · Rosa Bartolomeo, Fulvia Troise, et al. · Vaccines · 3
PDF
Data from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses
2024 · Anna Morena D'Alise, Guido Leoni, et al. · 1
Supplementary Figure 1 from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses
2024 · Anna Morena D'Alise, Guido Leoni, et al.
Supplementary Table 1 from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses
2024 · Anna Morena D'Alise, Guido Leoni, et al.
PDF
Abstract B105: A cancer vaccine targeting many neoantigens is required for effective eradication of large tumors
2019 · Anna Morena D'Alise, Guido Leoni, et al. · Cancer Immunology Research
Works count: 13
Citation count: 988
H-index: 6
I10-index: 6
Year
Topic
Type